Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
reembolso del 75% del coste de Búsquedas e Informes Tecnológicos de Patentes. Más información*
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
135
resultados
Última actualización
01/09/2024 [07:12:00]
Resultados 75 a 100 de 135
Resumen de: CN118005709A
The invention belongs to the technical field of biological medicine, and discloses a CDDO-Me/Ozanimod co-prodrug based on azo reductase activation and a preparation method and application thereof.The co-prodrug has the structure shown in the general formula I: # imgabs0 #. The CDDO-Me/Ozanimod co-prodrug can be specifically activated by azo reductase in intestinal inflammation, fluorescence is generated, active raw drugs CDDO-Me and Ozanimod are released through a 1, 6 elimination reaction, and the co-prodrug can be used for preparing a drug for treating intestinal inflammation. The traditional Chinese medicine composition is used for diagnosing and treating colitis. The co-prodrug provided by the invention not only can provide accurate inflammation diagnosis based on fluorescence, but also can gather in a targeted manner at the intestinal tract part, so that the selective accumulation of the two parent drugs in the intestinal tract is increased, and the therapeutic effects of selective fluorescence tracing and synergistic and efficient colitis resistance are exerted.
Resumen de: WO2024094817A1
The present invention relates to a score (TOPOSCORE) for describing eubiosis or dysbiosis in an individual, that can be used, inter alia, for determining if a patient is likely to respond to an immune-oncology treatment, more precisely, a treatment comprising administration of an immune checkpoint inhibitor (ICI). The TOPOSCORE represents a robust biomarker predicting immunosensitivity and immunoresistance to ICI on an individual basis.
Resumen de: US2020368291A1
An object of the present invention is to provide a cell population comprising safe adherent stem cells maintaining a normal karyotype and a method for producing the cell population, and a pharmaceutical composition comprising the cell population. According to the present invention, a production method of a cell population comprising adherent stem cells, comprising obtaining a cell population in which the proportion of KCNAB1-positive adherent stem cells in the cell population is 85% or more, is provided.
Resumen de: US2024150453A1
The subject matter disclosed herein is generally directed to stratifying and treating inflammatory diseases. In particular, the present invention provides for detecting treatment naive cell states that predict the response of a subject having inflammatory bowel disease to anti-TNF-blockade. The cells are T cells, NK cells, innate lymphoid cells, myeloid and/or epithelial cell subsets defined by their gene expression as determined by single cell RNA sequencing. Alternatively, the responders are identified by gene expression in a sample.
Resumen de: CN117987533A
The invention relates to a biomarker for periodontitis with aggravated inflammatory bowel disease activity and application of the biomarker, and belongs to the technical field of biological medicine. According to the application of DEFA5 as the biomarker of periodontitis with aggravated inflammatory bowel disease, periodontitis immune inflammatory response abnormity can be effectively recognized, and meanwhile timely guidance treatment and prognosis judgment are conducted on periodontal immune inflammatory response abnormity. The invention further provides a medicine for treating periodontitis with aggravated inflammatory bowel disease activity, and the medicine can effectively treat periodontal macrophage damage caused by DEFA5, recover the phagocytic function of periodontal macrophages, reduce colonization of fusobacterium nucleatum at periodontal and colon parts and effectively relieve inflammation at the periodontal and colon parts.
Resumen de: CN117986368A
The invention relates to the technical field of biological science, in particular to an anti-tumor and anti-inflammation related nano antibody as well as a preparation method and application thereof. The invention provides an anti-tumor and anti-inflammation related nano antibody, the nano antibody comprises a nano antibody VHH02-8D, the amino acid sequence of the nano antibody VHH02-8D is shown as Seq. ID NO. 1, and the amino acid sequence of the nano antibody VHH02-8D is shown as Seq. ID NO. The nano antibody VHH02-8D can be specifically combined with tumor and inflammation related protein MMP9, can effectively inhibit the activity of MMP9 protease and can be used as an MMP9 inhibitor, and the provided nano antibody VHH02-8D plays a good role in treating breast cancer, colon cancer and inflammatory bowel disease models of mice, and can be used as an anti-tumor drug. The inflammatory response of colitis can be well relieved by inhibiting the activity of the MMP9 enzyme, and the compound can be used for preparing anti-tumor and anti-inflammation related drugs and is wide in application range.
Resumen de: WO2024086955A1
The present invention relates to a method for obtaining a circulating mitochondria-enriched composition, avoiding platelet activation. This method obtains a circulating mitochondria-enriched composition comprising a high concentration of circulating mitochondria and at the same time comprising a low concentration of positive mitochondria for the CD42b, CD42A and/or CD41 markers. This composition is used to prepare a drug useful for counteracting CD4+ T lymphocyte hyperactivation. These CD4+ T lymphocytes are hyperactive in acute inflammatory processes or in autoimmune diseases. These autoimmune diseases include: Systemic Lupus Erythematosus (SLE); Rheumatoid arthritis; Psoriasis; Antiphospholipid syndrome; Multiple sclerosis; Atherosclerosis; Osteoarthritis; Type I diabetes; Sjögren's syndrome; Myasthenia gravis; Crohn's disease; Ulcerative colitis; Vasculitis; Vasculitis associated with anti-neutrophil cytoplasmic antibodies; Graft-versus-host disease; Preeclampsia and/or Celiac disease.
Resumen de: CN116183929A
Contemplated kits and methods for food sensitivity are based on reasonable selection of food preparations with established discriminant p values. Particularly preferred kits include kits with a minimum number of food preparations having an average discriminant p value of < = 0.07, determined from their original p values, or an average discriminant p value of < = 0.10, determined from FDR multiple corrected p values. In further contemplated aspects, the compositions and methods for food sensitivity are also stratified by gender to further enhance predictive values.
Resumen de: CN117949648A
The invention provides a marker for detecting inflammatory bowel disease (IBD) and application of the marker. The marker relates to secondary bile acid glydeoxycholic acid and derivatives of the secondary bile acid glydeoxycholic acid. According to the application, non-targeted metabonomics screening and bile acid targeted metabonomics detection are carried out on a colon sample, and the glydeoxycholic acid and the derivative thereof are found to be related to ulcerative colitis disease activity diagnosis and can be used for screening, diagnosis, recurrence prediction or treatment effect evaluation of diseases.
Resumen de: CN117946964A
The invention discloses an in-vitro intestinal disease model as well as a construction method and application thereof. The construction method of the in-vitro intestinal disease model comprises the step of inducing an in-vitro intestinal tract by using a solution containing IFN-gamma or IFN alpha to obtain the model. The method is easy to operate, and complex surgical instrument operation and instrument detection are not needed; the in-vitro intestinal disease model can be used for evaluating the drug effects of different inhibitors in drugs for evaluating inflammatory bowel disease related pathways, TYK2 and/or JAK1 pathways.
Resumen de: WO2024085698A1
The present invention provides a pharmaceutical composition for the prevention or treatment of inflammatory bowel disease, comprising a glycogen phosphorylase (PYGL) inhibitor as an active ingredient, and a method for screening for a material for the prevention or treatment of inflammatory bowel disease. By using the pharmaceutical composition for the prevention or treatment of inflammatory bowel disease, comprising a PYGL inhibitor as an active ingredient, according to the present invention, inflammatory bowel disease such as ulcerative colitis can be prevented or treated. Also, through the method for screening for a material for the prevention or treatment of inflammatory bowel disease, according to the present invention, a material that reduces PYGL activity can be determined as a candidate material for the prevention or treatment of inflammatory bowel disease.
Resumen de: CN117924509A
The invention relates to the field of immunology, in particular to bispecific antibodies simultaneously targeting integrin alpha4beta7 and TNF-alpha, nucleic acid molecules, vectors and host cells encoding the bispecific antibodies, derivatives of the bispecific antibodies and application of the bispecific antibodies to disease treatment.
Resumen de: CN117929704A
The invention discloses a detection kit for detecting inflammatory bowel disease through an excrement sample. The detection kit comprises a phosphate buffer solution, acetone, an SDS-PAGE gel protein separation reagent and a TAF1A protein antibody, and the TAF1A protein antibody is used for detecting TAF1A protein in the excrement sample. The detection kit provided by the invention is helpful for detecting early intestinal inflammatory lesions, and the probability of false positive occurrence in detection is reduced.
Resumen de: WO2024086683A2
Provided herein is a peptide array comprising a plurality of flagellin peptides corresponding to highly conserved peptide regions. For example, the peptide array comprises a plurality of Lachnospiraceae flagellin peptides, which can be selected from a hinge region of Lachnospiraceae flagellin. Also provided is antibody of fragment thereof that binds to one or more of the plurality of the flagellin peptides in the peptide array. The peptide array and antibody are useful in determining an immunosignature from a biological sample from a subject. The immunosignature is useful in diagnosis of an immune-mediated disease, in monitoring progression of an immune-mediated disease, in identifying subjects susceptible to certain treatments, and in monitoring treatment response.
Resumen de: WO2024085698A1
The present invention provides a pharmaceutical composition for the prevention or treatment of inflammatory bowel disease, comprising a glycogen phosphorylase (PYGL) inhibitor as an active ingredient, and a method for screening for a material for the prevention or treatment of inflammatory bowel disease. By using the pharmaceutical composition for the prevention or treatment of inflammatory bowel disease, comprising a PYGL inhibitor as an active ingredient, according to the present invention, inflammatory bowel disease such as ulcerative colitis can be prevented or treated. Also, through the method for screening for a material for the prevention or treatment of inflammatory bowel disease, according to the present invention, a material that reduces PYGL activity can be determined as a candidate material for the prevention or treatment of inflammatory bowel disease.
Resumen de: WO2024085195A1
Provided is an examination method for irAE enteritis, said examination method comprising a detection step for detecting, as an indicator of ulcerous colitis-like irAE enteritis, an antibody that immunologically reacts with a fragment of, or the entirety of, integrin αvβ6 in a specimen.
Resumen de: CN117907608A
The invention discloses a Claudin2 protein detection method as well as a related product and application thereof, and relates to the field of biology. The invention provides an extraction liquid which comprises cathepsin S or elastinase 1 and cathepsin E. The Claudin2 protein can be effectively extracted from an excrement sample by adopting the extraction liquid, and the Claudin2 protein is dissolved in excrement supernatant, so that the target protein Claudin2 is detected from the excrement sample, and non-invasive effective detection of the Claudin2 protein is realized.
Resumen de: CN117898258A
The invention relates to a Toll-like receptor 5 gene condition overexpression animal model. Specifically, the invention provides a preparation method of a TLR5 gene conditional overexpression non-human model animal, which comprises the following steps: obtaining Cas9mRNA and gRNA in an in-vitro transcription mode; according to the method, a homologous recombinant vector is constructed, the vector comprises a 5'homologous arm, a TLR5 gene expression cassette and a 3 'homologous arm, the TLR5 gene expression cassette is a silent expression cassette, and under the induction condition, the silent expression cassette is converted into an activated TLR5 gene expression cassette. Cas9mRNA, gRNA and a homologous recombinant vector are injected into a fertilized egg in vitro, and the injected fertilized egg is obtained. And regenerating the injected fertilized eggs into the TLR5 gene conditional overexpression animal model. The animal model provided by the invention has wide application prospects in the aspects of virus resistance, bacterial immunity, tumor immunity, inflammatory bowel disease diagnosis and treatment and the like.
Resumen de: US2024122995A1
This document discusses, among other things, receiving a plurality of donor fecal samples from a plurality of donors and storing and indexing each respective donor fecal samples using at least one characteristic of the respective donor fecal sample. In an example, the donor fecal sample can be screened and processed for subsequent use in fecal bacteriotherapy to displace pathogenic or undesired organisms in the digestive track of a patient with healthy or desirable gut microbiota.
Resumen de: AU2022289038A1
Provided herein are methods for diagnosing functional gastrointestinal disorders such as functional dyspepsia and irritable bowel syndrome, comprising detecting IgG antibodies in a sample obtained from a subject, wherein the IgG antibodies recognise one or more antigens from Streptococcus salivarius. Also provided are kits for detecting IgG antibodies for use in the diagnosis of functional gastrointestinal disorders, and methods for selecting subjects for treatment for functional gastrointestinal disorders.
Resumen de: WO2024076967A1
The present invention provides compositions and methods for reducing the level and/or activity of a TET protein, for treating or preventing a disease and disorder associated with an increased level and/or activity of a TET protein, for reducing, stopping, or reversing weight loss, for inducing apoptosis in disease-associated macrophage (e.g., endometriosis-associated macrophage and tumor-associated macrophage) and/or cancer-associated fibroblast, and/or for preventing or treating various diseases or disorder (e.g., endometriosis, non-alcoholic steatohepatitis, inflammatory disease or disorder, chronic inflammatory disease or disorder, inflammatory bowel disease, Alzheimer's disease, Parkinson's disease, cancer, and/or cancer- associated diseases or disorders). In various embodiments, the method comprises administering a degrader of TET protein, inhibitor of TET protein, or a combination thereof as a therapeutic.
Resumen de: CA3219846A1
The present disclosure is generally relates to methods of treating and diagnosing ulcerative colitis. The methods are particularly suitable for treating and diagnosing a specific sub-group of patients with ulcerative colitis. The methods are also particularly suitable for treating and diagnosing urgency in a patient having or suspected of having ulcerative colitis. The methods are also particularly suitable for treating and diagnosing stool frequency and bowel urgency in a patient having or suspected of having ulcerative colitis.
Resumen de: US2024094224A1
Proxies for physiological states of tissue are provided. Accordingly, there are provided methods of determining host AMP landscape, establishing a profile indicative of tissue status, and identifying proxies for tissue status in AMP profiles of samples of secretions, exudates and/or excretions of the tissue. Also provided are methods for determination of disease severity and chronology.
Resumen de: CN117843770A
The invention discloses preparation and application of a high-affinity scFv antibody for resisting an infectious bursal disease virus. The scFv antibody provided by the invention comprises a heavy chain variable region, a light chain variable region and a connecting region between the heavy chain variable region and the light chain variable region, eight scFv antibodies are screened by using an antigen-antibody co-expression bacterial display technology and have high affinity with IBDV VP2 protein and different IBDV virus strains, and the scFv antibodies with high affinity and neutralizing activity can be screened by constructing a mutant library and are used for preventing and treating IBD; the kit can also be used for detecting IBDV pathogens by an ELISA method.
Nº publicación: CN117843766A 09/04/2024
Solicitante:
NORTHEAST AGRICULTURAL UNIV
\u4E1C\u5317\u519C\u4E1A\u5927\u5B66
Resumen de: CN117843766A
The invention discloses preparation and application of a high-affinity scFv antibody for resisting an infectious bursal disease virus. The scFv antibody provided by the invention comprises a heavy chain variable region, a light chain variable region and a connecting region between the heavy chain variable region and the light chain variable region, eight scFv antibodies are screened by using an antigen-antibody co-expression bacterial display technology and have high affinity with IBDV VP2 protein and different IBDV virus strains, and the scFv antibodies with high affinity and neutralizing activity can be screened by constructing a mutant library and are used for preventing and treating IBD; the kit can also be used for detecting IBDV pathogens by an ELISA method.
BOPI
Sede Electrónica
